Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy

PURPOSE: Addition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Support Care Cancer
Prif Awduron: Chasen, Martin, Urban, Laszlo, Schnadig, Ian, Rapoport, Bernardo, Powers, Dan, Arora, Sujata, Navari, Rudolph, Schwartzberg, Lee, Gridelli, Cesare
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2016
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5127871/
https://ncbi.nlm.nih.gov/pubmed/27557833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-016-3388-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg